Company Overview - Ovid Therapeutics Inc. (OVID) is a CNS drug developer focusing on therapies for disorders related to neuronal hyperexcitability [1] Pipeline Focus - OVID's pipeline primarily targets two mechanisms: 1) A GABA-AT inhibitor aimed at treating uncontrolled epilepsy 2) KCC2 [1]

Company Overview - Ovid Therapeutics Inc. (OVID) is a CNS drug developer focusing on therapies for disorders related to neuronal hyperexcitability [1] - The company's pipeline primarily targets two mechanisms: a GABA-AT inhibitor for uncontrolled epilepsy and KCC2 [1] Analyst Background - The article includes a brief background of Myriam Hernandez Alvarez, who holds multiple degrees in engineering, computer science, business management, and computer applications [1] Disclosure Information - The article contains disclosures regarding the author's lack of stock or derivative positions in the mentioned companies and no plans to initiate such positions [2] - It emphasizes that the opinions expressed are independent and not influenced by any business relationships [2]